Emma Bowden currently serves as Vice President and Head of Clinical Development at QurAlis, beginning in October 2023. Prior experience includes a Vice President role at Nutcracker Therapeutics and a significant tenure at Sangamo Therapeutics, Inc. from May 2021 to May 2023, where responsibilities encompassed overseeing complex global gene therapy trials and driving clinical strategy. Emma has also held leadership positions at Eli Lilly and Company, Thermo Fisher Scientific, and MedImmune, demonstrating expertise in clinical development, regulatory interactions, and strategic program management across various therapeutic areas. With a PhD in Biochemistry from the University of Bristol, Emma has contributed significantly to research and development initiatives while maintaining collaborations with academic and industry partners.
Org chart
Teams
Offices
This person is not in any offices
QurAlis
1 followers
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. They are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.
